Indications for NUPLAZID:

Treatment of hallucinations and delusions associated with Parkinson's disease (PD) psychosis.


34mg once daily ­without titration. Concomitant strong CYP3A4 inhibitors: 10mg once daily. Concomitant strong CYP3A4 inducers: monitor and dose increase may be needed.


Not established.

Boxed Warning:

Increased mortality in elderly patients with dementia-related psychosis.


Elderly with dementia-related psychosis: increased risk of death. Not for treating patients with dementia-related psychosis unrelated to the hallucinations/delusions associated with PD psychosis. Avoid in patients with known or congenital QT prolongation, history of cardiac arrhythmias, symptomatic bradycardia, hypokalemia, or hypomagnesemia. Severe renal impairment (CrCl <30mL/min), ESRD. Pregnancy. Nursing mothers.

See Also:

Pharmacologic Class:

Atypical antipsychotic.


Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, clarithromycin, indinavir); see Adults. Antagonized by strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John's wort). Avoid concomitant drugs known to prolong QT interval including Class 1A (eg, quinidine, procainamide, disopyramide) or Class 3 antiarrhythmics (eg, amiodarone, sotalol), certain antipsychotics (eg, ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (eg, gatifloxacin, moxifloxacin).

Adverse Reactions:

Peripheral edema, confusional state, nausea, hallucination, constipation, gait disturbance.

Generic Availability:


How Supplied:

Tabs, caps—30

Pricing for NUPLAZID

17mg tablet (Qty: 60)
Appx. price $2758